Business
Zymeworks Announces Results of Special Meeting
VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)-- Zymeworks Inc. (“Zymeworks” or the “Company”) (NYSE: ZYME), a clinical-stage biopharmaceutical
About this update from Zymeworks Inc.
[{"type":"text","content":" VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--\nZymeworks Inc. (“Zymeworks” or the “Company”) (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, is pleased to announce that the Company’s securityholders have approved its plan to become a Delaware corporation (the “Redomicile”) at the special meeting of Zymeworks securityholders (the “Special Meeting”) held in Vancouver, BC, on October 7, 2022.\n\nAt the Special Meeting, a total of 30,955,015 Zymeworks common shares were present in person or by proxy, representing approximately 50.17% of the Zymeworks common shares issued and outstanding and entitled to vote at the Special Meeting as of the record date of August 24, 2022 (the “Record Date”), and a total of 36,496,322 Zymeworks common shares, warrants and incentive awards were present in person or by proxy, representing approximately 48.91% of the Zymeworks common shares, warrants and incentive awards issued and outstanding and entitled to vote at the Special Meeting as of the Record Date.\n\nThe results of the vote were as follows:\n\n\n\n \n\n\n\n# Votes For\n\n\n \n\n% Votes For\n\n\n \n\n# Votes Against\n\n\n \n\n% Votes Against\n\n\n \n\n# Votes Abstain\n\n\n \n\n% Votes Abstain\n\n\n\n\n\nZymeworks shareholders, warrantholders and incentive award holders, voting together as a single class\n\n\n\n34,612,420\n\n\n \n\n94.84%\n\n\n \n\n1,830,919\n\n\n \n\n5.02%\n\n\n \n\n52,983\n\n\n \n\n0.14%\n\n\n\n\n\nZymeworks shareholders, voting separately\n\n\n\n29,073,873\n\n\n \n\n93.92%\n\n\n \n\n1,828,159\n\n\n \n\n5.91%\n\n\n \n\n52,983\n\n\n \n\n0.17%\n\n\n\n\n“We wish to thank our securityholders for their ongoing support and strong endorsement of this plan,” said Kenneth Galbraith, Chair and CEO of Zymeworks. “Today’s result is an important step in our corporate development that we believe will facilitate an expanded investor base for Zymeworks, as well as simplify commercialization efforts and monetization opportunities for zanidatamab, zanidatamab zovodotin and our future product candidates.”\n\nAdditional details of the results of the Special Meeting will be filed under the Company’s profile on SEDAR at www.sedar.com. The Company intends to file a Current Report on Form 8-K within four business days of the meeting date reporting the results of the Special Meeting.\n\...